Dr. Mauguen’s methodological research focuses on survival analyses and the prediction of survival endpoints. She is particularly interested in using information from complex covariates such as recurrent events and biomarker evolution. She also worked on improving the diagnostic and prediction of cancer risk by proposing a strategy to define cancer subtypes. Recently, her interests include analyzing somatic mutations and assessing the clonal relatedness between two tumors from a patient in order to distinguish between metastasis and second primary, a work in close collaboration with colleagues Colin Begg, Venkatraman Seshan and Irina Ostrovnaya. She is collaborating with clinical investigators from the Pediatric Department and from the Molecular Imaging and Therapy Service.
R package frailtypack: General Frailty Models: Shared, Joint and Nested Frailty Models with Prediction
R package Clonality: Testing for clonal relatedness versus independence of tumors from the same patient (first author: Irina Ostrovnaya)
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Audrey Mauguen discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures